Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
| | |

Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease

On Sept. 15, 2025, Corstasis Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved ENBUMYST™…

Lilly launches TuneLab platform to give biotech companies access to AI-enabled drug discovery models with over $1 billion in research investment
| | | |

Lilly launches TuneLab platform to give biotech companies access to AI-enabled drug discovery models with over $1 billion in research investment

On Sept. 9, 2025, Eli Lilly announced the launch of Lilly TuneLab, an artificial intelligence and machine learning…